Trenchant BioSystems agreed with Invetech to develop and commercialize the AutoCell fully automated cell and gene therapy (CGT) manufacturing platform. Internal and independent data indicate AutoCell could support workflows that remove or reduce ex vivo expansion steps and enable manufacturing from a single unit of whole blood, Trenchant said. Invetech will provide engineering and development support with an early access rollout targeted for select partners in 2027 and full commercial release later that year. The AutoCell program aims to enable distributed, point‑of‑care CGT manufacturing to lower costs of goods and shorten turnaround times for autologous and potentially allogeneic therapies.